Active Pharma Ingredients (API)
Dr. Reddy's offers an unparalleled portfolio to our customers comprising of innovators and generic formulators worldwide. With a strong product portfolio of products, including niches like oncology and hormones, and our “first in, last out” approach, it is little wonder that we are today among the leading generic API players globally. Our goal is to enable customers to be the first-to-launch a generic product as well as provide value-added services that help them remain competitive and profitable for the entire life cycle of the product.
We have built the capabilities to consistently deliver on this promise in scale and across the largest product range. Our expertise in organic synthesis and process development complemented by a controlled supply chain enables us to provide our customers with high quality Bulk Actives at competitive prices. We are aggressively building our product portfolio to cater to generic players in the emerging markets and generic and patent challenge formulators in regulated markets.
Our API business is supported by our technologically advanced Product Development infrastructure, which identifies new products and is engaged every step of the way, from the conceptual stage to delivery of drugs to the market place. The Product Delivery Teams, the Centres of Excellence and IP teams help create value through Intellectual Property and proactive patenting; early development work on certain promising molecules; breakthrough product delivery; and by delivering cost leadership in API.
Dr Reddys is one of the highest DMF filers worldwide , boasting of around 150 products in the portfolio, 40 in the pipeline, multiple filings in US, EU, Japan, Korea, Brazil and presence in almost 60 countries through API sales alone